B. Riley Covers Cumberland (CPIX) with $9.25 Target; Intevac (IVAC)’s Sentiment Is 1.13

Intevac, Inc. (NASDAQ:IVAC) Logo

Intevac Inc (IVAC) investors sentiment decreased to 1.13 in Q4 2017. It’s down -0.06, from 1.19 in 2017Q3. The ratio is negative, as 35 active investment managers increased and started new positions, while 31 sold and decreased stock positions in Intevac Inc. The active investment managers in our database now possess: 15.44 million shares, up from 15.18 million shares in 2017Q3. Also, the number of active investment managers holding Intevac Inc in top ten positions was flat from 0 to 0 for the same number . Sold All: 9 Reduced: 22 Increased: 25 New Position: 10.

In a a research note sent to clients and investors today, B. Riley analysts began Cumberland (NASDAQ:CPIX) coverage with a “Buy” rating, and a $9.25 price target.

Analysts await Intevac, Inc. (NASDAQ:IVAC) to report earnings on April, 30 after the close. They expect $-0.23 earnings per share, down 387.50% or $0.31 from last year’s $0.08 per share.

Since January 1, 0001, it had 9 insider purchases, and 0 sales for $2.35 million activity.

Intevac, Inc. provides vacuum deposition equipment for various thin-film applications, and digital night-vision technologies and products to the defense industry in the United States, Asia, and Europe. The company has market cap of $143.10 million. It operates through two divisions, Thin-film Equipment and Photonics. It has a 35.56 P/E ratio. The Thin-film Equipment segment designs, makes, markets, and services disk sputtering systems, etch and deposition systems, and disk lubrication systems; and offers upgrades, and spares and consumables, as well as provides process and applications support, customer training, installation, start-up assistance, and post-installation service support services.

The stock increased 0.39% or $0.03 during the last trading session, reaching $6.4. About 52,821 shares traded. Intevac, Inc. (IVAC) has declined 48.95% since April 17, 2017 and is downtrending. It has underperformed by 60.50% the S&P500.

Pacific Ridge Capital Partners Llc holds 0.31% of its portfolio in Intevac, Inc. for 171,000 shares. Schneider Capital Management Corp owns 186,199 shares or 0.28% of their US portfolio. Moreover, Essex Investment Management Co Llc has 0.18% invested in the company for 199,539 shares. The New York-based Teton Advisors Inc. has invested 0.14% in the stock. Aimz Investment Advisors Llc, a California-based fund reported 23,821 shares.

Since March 19, 2018, it had 1 buying transaction, and 0 insider sales for $2,016 activity. Bonner Michael bought $2,016 worth of stock or 300 shares.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, together with its subsidiaries, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. The company has market cap of $105.65 million. The Company’s marketed products include Acetadote injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for the treatment of chronic and acute constipation; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Ethyol (amifostine) for injection to treat oncology patients; and Totect Injection for the treatment of toxic effects. It currently has negative earnings. The company's product candidates in Phase II clinical trials comprise Hepatoren (ifetroban) injection for the treatment of hepatorenal syndrome; Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease; Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension.

The stock increased 5.14% or $0.33 during the last trading session, reaching $6.75. About 11,919 shares traded. Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) has risen 4.86% since April 17, 2017 and is uptrending. It has underperformed by 6.69% the S&P500.

Investors sentiment increased to 0.86 in Q4 2017. Its up 0.22, from 0.64 in 2017Q3. It increased, as 5 investors sold Cumberland Pharmaceuticals Inc. shares while 9 reduced holdings. 3 funds opened positions while 9 raised stakes. 4.12 million shares or 0.62% less from 4.14 million shares in 2017Q3 were reported. State Street Corporation owns 10,046 shares. State Common Retirement Fund holds 257,976 shares. Renaissance Tech Ltd Company, a New York-based fund reported 330,300 shares. Invesco Limited reported 0% stake. California Employees Retirement Sys reported 53,800 shares or 0% of all its holdings. 10,000 were reported by Cambridge Invest Rech Advsrs. 48,610 are held by Geode Cap Management Limited Com. Ariel Invs Ltd Llc holds 0.08% of its portfolio in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) for 910,076 shares. 11,000 are held by Delta Asset Mngmt Ltd Tn. Thompson Davis Incorporated owns 1,250 shares. Moreover, Blackrock has 0% invested in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) for 377,217 shares. Northern Tru owns 24,875 shares. 20,338 were reported by Fincl Bank Of New York Mellon Corp. Vanguard Group reported 316,237 shares stake. Spark Investment Management Limited Liability has 13,200 shares.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Institutional Positions Chart